FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113420021> ?p ?o ?g. }

• W2113420021 endingPage "670" @default.
• W2113420021 startingPage "665" @default.
• W2113420021 abstract "Background: The objective of this study was to determine the feasibility and maximum tolerated dose (MTD) of combination topotecan and pegylated liposomal doxorubicin (PLD) administered in 4- or 3-week cycles in patients with advanced or refractory solid tumors. Patients and Methods: Patients were treated with intravenous topotecan (0.75–1.25 mg/m2) for 3 days followed by PLD (25–40 mg/m2) on Day 4. The following dose combinations (topotecan/PLD, mg/m2) were explored: 0.75/40, 1.0/40, and 1.25/40 every 28 days; and 1.0/25 and 1.0/30 every 21 days. Results: Thirty-two patients were enrolled, and all had received prior chemotherapy. Most (84 percent) patients had ovarian cancer. A total of 157 cycles (median, 4 cycles; range, 1–19 cycles) of chemotherapy were administered. Dose-limiting toxicities were Grade 4 neutropenia and death at dose level 3 (1.25/40 mg/m2 every 28 days), and neutropenic fever, Grade 3 stomatitis, and Grade 3 peripheral neuropathy (all in one patient) at dose level 5 (1/30 mg/m2 every 21 days). Myelosuppression was the most common serious toxicity. Twenty-six patients were evaluable for response and 7 (27 percent) had partial responses. All responses were seen in patients with ovarian cancer. Conclusions: This combination is feasible and well tolerated; encouraging activity was observed in heavily pretreated patients with ovarian cancer. The recommended regimens for a Phase II study are topotecan 1.0 mg/m2 on Days 1–3 followed by PLD 40 mg/m2 on Day 4 of a 28-day cycle, and topotecan 1.0 mg/m2 on Days 1–3 and PLD 30 mg/m2 on Day 4 of a 21-day cycle." @default.
• W2113420021 created "2016-06-24" @default.
• W2113420021 creator A5021587183 @default.
• W2113420021 creator A5045207018 @default.
• W2113420021 creator A5054205659 @default.
• W2113420021 creator A5071585351 @default.
• W2113420021 creator A5075566972 @default.
• W2113420021 creator A5079063238 @default.
• W2113420021 creator A5091834693 @default.
• W2113420021 date "2005-01-01" @default.
• W2113420021 modified "2023-10-18" @default.
• W2113420021 title "Phase I Clinical Trial of Topotecan and Pegylated Liposomal Doxorubicin" @default.
• W2113420021 cites W1589920570 @default.
• W2113420021 cites W1769308960 @default.
• W2113420021 cites W1804680040 @default.
• W2113420021 cites W1913802169 @default.
• W2113420021 cites W1919288105 @default.
• W2113420021 cites W1930683464 @default.
• W2113420021 cites W1960327677 @default.
• W2113420021 cites W1969426157 @default.
• W2113420021 cites W1972483602 @default.
• W2113420021 cites W1979740289 @default.
• W2113420021 cites W1999879350 @default.
• W2113420021 cites W2019995515 @default.
• W2113420021 cites W2055513480 @default.
• W2113420021 cites W2066933615 @default.
• W2113420021 cites W2124273755 @default.
• W2113420021 cites W2153291245 @default.
• W2113420021 cites W2160684474 @default.
• W2113420021 cites W2167974749 @default.
• W2113420021 doi "https://doi.org/10.1080/07357900500359877" @default.
• W2113420021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16377584" @default.
• W2113420021 hasPublicationYear "2005" @default.
• W2113420021 type Work @default.
• W2113420021 sameAs 2113420021 @default.
• W2113420021 citedByCount "15" @default.
• W2113420021 countsByYear W21134200212014 @default.
• W2113420021 countsByYear W21134200212015 @default.
• W2113420021 countsByYear W21134200212016 @default.
• W2113420021 countsByYear W21134200212022 @default.
• W2113420021 crossrefType "journal-article" @default.
• W2113420021 hasAuthorship W2113420021A5021587183 @default.
• W2113420021 hasAuthorship W2113420021A5045207018 @default.
• W2113420021 hasAuthorship W2113420021A5054205659 @default.
• W2113420021 hasAuthorship W2113420021A5071585351 @default.
• W2113420021 hasAuthorship W2113420021A5075566972 @default.
• W2113420021 hasAuthorship W2113420021A5079063238 @default.
• W2113420021 hasAuthorship W2113420021A5091834693 @default.
• W2113420021 hasConcept C121332964 @default.
• W2113420021 hasConcept C121608353 @default.
• W2113420021 hasConcept C126322002 @default.
• W2113420021 hasConcept C141071460 @default.
• W2113420021 hasConcept C142424586 @default.
• W2113420021 hasConcept C2776694085 @default.
• W2113420021 hasConcept C2777063308 @default.
• W2113420021 hasConcept C2779051857 @default.
• W2113420021 hasConcept C2780427987 @default.
• W2113420021 hasConcept C2781209748 @default.
• W2113420021 hasConcept C2781303535 @default.
• W2113420021 hasConcept C2781413609 @default.
• W2113420021 hasConcept C29730261 @default.
• W2113420021 hasConcept C31760486 @default.
• W2113420021 hasConcept C71924100 @default.
• W2113420021 hasConcept C87355193 @default.
• W2113420021 hasConcept C90924648 @default.
• W2113420021 hasConcept C98274493 @default.
• W2113420021 hasConceptScore W2113420021C121332964 @default.
• W2113420021 hasConceptScore W2113420021C121608353 @default.
• W2113420021 hasConceptScore W2113420021C126322002 @default.
• W2113420021 hasConceptScore W2113420021C141071460 @default.
• W2113420021 hasConceptScore W2113420021C142424586 @default.
• W2113420021 hasConceptScore W2113420021C2776694085 @default.
• W2113420021 hasConceptScore W2113420021C2777063308 @default.
• W2113420021 hasConceptScore W2113420021C2779051857 @default.
• W2113420021 hasConceptScore W2113420021C2780427987 @default.
• W2113420021 hasConceptScore W2113420021C2781209748 @default.
• W2113420021 hasConceptScore W2113420021C2781303535 @default.
• W2113420021 hasConceptScore W2113420021C2781413609 @default.
• W2113420021 hasConceptScore W2113420021C29730261 @default.
• W2113420021 hasConceptScore W2113420021C31760486 @default.
• W2113420021 hasConceptScore W2113420021C71924100 @default.
• W2113420021 hasConceptScore W2113420021C87355193 @default.
• W2113420021 hasConceptScore W2113420021C90924648 @default.
• W2113420021 hasConceptScore W2113420021C98274493 @default.
• W2113420021 hasIssue "8" @default.
• W2113420021 hasLocation W21134200211 @default.
• W2113420021 hasLocation W21134200212 @default.
• W2113420021 hasOpenAccess W2113420021 @default.
• W2113420021 hasPrimaryLocation W21134200211 @default.
• W2113420021 hasRelatedWork W1978453679 @default.
• W2113420021 hasRelatedWork W1981260623 @default.
• W2113420021 hasRelatedWork W2017134869 @default.
• W2113420021 hasRelatedWork W2155041167 @default.
• W2113420021 hasRelatedWork W2225907637 @default.
• W2113420021 hasRelatedWork W2349518346 @default.
• W2113420021 hasRelatedWork W2385947617 @default.
• W2113420021 hasRelatedWork W2397482356 @default.
• W2113420021 hasRelatedWork W2604112126 @default.

• next